Ascletis Pharma Inc. (ASCLF)
OTCMKTS
· Delayed Price · Currency is USD
0.9325
+0.0394 (4.41%)
At close: May 30, 2025
Ascletis Pharma Revenue
In the year 2024, Ascletis Pharma had annual revenue of 1.28M CNY, down -97.73%. Ascletis Pharma had revenue of 1.28M in the half year ending December 31, 2024, a decrease of -91.92%.
Revenue
1.28M CNY
Revenue Growth
-97.73%
P/S Ratio
6,712.96
Revenue / Employee
5.55K CNY
Employees
231
Market Cap
1.18B USD
Revenue Chart
* This company reports financials in CNY.
Revenue History
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Endo, Inc. | 1.73B |
| Veradigm | 588.02M |
| Elite Pharmaceuticals | 70.00M |
| Tian'an Technology Group | 1.78M |
| American Oncology Network | 1.76B |
| Glass House Brands | 215.62M |
| Northwest Biotherapeutics | 1.47M |
| Silence Therapeutics | 27.70M |
Ascletis Pharma News
- 3 days ago - Ascletis Announces First Participants Dosed in U.S. Phase I Clinical Study of ASC50, a Potential Best-in-Class Oral Small Molecule IL-17 Inhibitor for the Treatment of Psoriasis - PRNewsWire
- 12 days ago - Ascletis Announces Poster Presentations on the Study Results of ASC30 and ASC47 at the 85th Scientific Sessions of American Diabetes Association (ADA) - PRNewsWire
- 17 days ago - Ascletis Announces Phase III Trial of Denifanstat (ASC40), a First-in-Class, Once-Daily Oral FASN Inhibitor for Acne, Meets All Endpoints - PRNewsWire
- 4 weeks ago - Ascletis Announces U.S. FDA Clearance of IND Application for Its Oral Small Molecule IL-17 Inhibitor, ASC50, for the Treatment of Psoriasis - PRNewsWire
- 4 weeks ago - Ascletis Announces First Participants Dosed in a U.S. Clinical Study Combining Adipose-Targeted, Once-Monthly Injectable Small Molecule THRβ Agonist, ASC47, and Semaglutide for the Treatment of Obesity - PRNewsWire
- 6 weeks ago - Ascletis Announces Oral and Poster Presentations on ASC47, an Adipose-Targeted, Muscle-Preserving Weight Loss Drug Candidate for Obesity at the 32nd European Congress on Obesity - PRNewsWire
- 2 months ago - Ascletis Announces Positive Topline Results of U.S. Phase Ib Multiple Ascending Dose Study of Small Molecule Oral GLP-1R Agonist ASC30 and Submission of 13-week Phase IIa Study Protocol to FDA - PRNewsWire
- 2 months ago - Ascletis Announces Positive Interim Results from Its U.S. Phase Ib Trial with ASC30, a Potentially First-in-Class Subcutaneous Injection Small Molecule GLP-1R Agonist - PRNewsWire